Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,043 mentions
- robotic manipulationmarket824 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology371 mentions
- agentic AItechnology353 mentions
- vision-language-action modeltechnology350 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology318 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology175 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
ATR-04
product4 mentionslast seen Nov 10, 2026
Investigational live biotherapeutic containing an isolated Staphylococcus epidermidis strain for treatment of EGFR inhibitor-associated skin rash.
Relationships 10
- Azitra, Inc.developsATR-0499% confidence4 sources
- U.S. Food and Drug AdministrationapprovesATR-0499% confidence3 sources
- ATR-04applies toEGFR inhibitor-associated skin rash treatment97% confidence1 source
- ATR-04applies tocancer treatment-associated skin rash93% confidence1 source
- ATR-04applies toEGFR inhibitor associated rash treatment92% confidence1 source
- ATR-04applies toKRAS and MEK inhibitor-associated skin rash91% confidence1 source
- ATR-04applies toEGFR inhibitor-associated skin rash90% confidence1 source
- ATR-04applies toneurofibromatosis type 1 with MEK inhibitor-associated rash90% confidence1 source
- ATR-04applies tocancer treatment-associated rash88% confidence1 source
- ATR-04depends onlive biotherapeutic88% confidence1 source
Relationship
U.S. Food and Drug AdministrationapprovesATR-04
99% confidence3 supporting mentions
Either name opens that entity’s relationships.
Sources 3
- filingSEC EDGAROct 29, 2026Azitra, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
The U.S. Food and Drug Administration (the "FDA") has granted Fast Track designation to ATR04-484
- filingSEC EDGAROct 26, 2026Azitra, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Azitra has received Fast Track designation from the FDA for EGFRi associated rash
- filingSEC EDGAROct 1, 2026Azitra, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
The U.S. Food and Drug Administration (the "FDA") has granted Fast Track designation to ATR04-484 for the treatment of EGFRi-associated rash